Insulin-like growth factor-I gene therapy reverses morphologic changes and reduces hyperprolactinemia in experimental rat prolactinomas

cic.isFulltexttruees
cic.isPeerReviewedtruees
cic.lugarDesarrolloUniversidad Nacional de La Plata es
cic.versioninfo:eu-repo/semantics/submittedVersiones
dc.date.accessioned2016-08-16T16:24:51Z
dc.date.available2016-08-16T16:24:51Z
dc.identifier.urihttps://digital.cic.gba.gob.ar/handle/11746/3682
dc.titleInsulin-like growth factor-I gene therapy reverses morphologic changes and reduces hyperprolactinemia in experimental rat prolactinomasen
dc.typeArtículoes
dcterms.abstractBackground: The implementation of gene therapy for the treatment of pituitary tumors emerges as a promising complement to surgery and may have distinct advantages over radiotherapy for this type of tumors. Up to now, suicide gene therapy has been the main experimental approach explored to treat experimental pituitary tumors. In the present study we assessed the effectiveness of insulin-like growth factor I (IGF-I) gene therapy for the treatment of estrogen-induced prolactinomas in rats. Results: Female Sprague Dawley rats were subcutaneously implanted with silastic capsules filled with 17-β estradiol (E2) in order to induce pituitary prolactinomas. Blood samples were taken at regular intervals in order to measure serum prolactin (PRL). As expected, serum PRL increased progressively and 23 days after implanting the E2 capsules (Experimental day 0), circulating PRL had undergone a 3-4 fold increase. On Experimental day 0 part of the E2-implanted animals received a bilateral intrapituitary injection of either an adenoviral vector expressing the gene for rat IGF-I (RAd-IGFI), or a vector (RAd-GFP) expressing the gene for green fluorescent protein (GFP). Seven days post vector injection all animals were sacrificed and their pituitaries morphometrically analyzed to evaluate changes in the lactotroph population. RAd-IGFI but not RAd-GFP, induced a significant fall in serum PRL. Furthermore, RAd-IGFI but not RAd-GFP significantly reversed the increase in lactotroph size (CS) and volume density (VD) induced by E2 treatment. Conclusion: We conclude that IGF-I gene therapy constitutes a potentially useful intervention for the treatment of prolactinomas and that bioactive peptide gene delivery may open novel therapeutic avenues for the treatment of pituitary tumors.en
dcterms.creator.authorCónsole, Gloria Miriames
dcterms.creator.authorHereñu, Claudia Beatrizes
dcterms.creator.authorCamihort, Giselaes
dcterms.creator.authorBracamonte, Maríaes
dcterms.creator.authorMorel, Gustavo R.es
dcterms.creator.authorGoya, Rodolfo G.es
dcterms.creator.authorLuna, Georgina Ceciliaes
dcterms.extent7 p.es
dcterms.identifier.other1476-4598es
dcterms.identifier.urlRegistro completoes
dcterms.isPartOf.issuevol. 7es
dcterms.isPartOf.seriesMolecular Canceres
dcterms.issued2008-01-01
dcterms.languageIngléses
dcterms.licenseAttribution 4.0 International (BY 4.0)es
dcterms.subjectadenovirus vectoren
dcterms.subjectgreen fluorescent proteinen
dcterms.subjectpeptideen
dcterms.subjectprolactinen
dcterms.subjectsomatomedin Cen
dcterms.subjectthymidine kinaseen
dcterms.subjecthyperprolactinemiaen
dcterms.subjecthypophysis cellen
dcterms.subjectimmunohistochemistryen
dcterms.subjectprolactinomaen
dcterms.subjectlactotrophsen
dcterms.subject.materiaCiencias Médicas y de la Saludes

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
luna - insulin-like.pdf-PDFA.pdf
Tamaño:
1.36 MB
Formato:
Adobe Portable Document Format
Descripción:
Documento completo